ContractWarrant Agreement • November 5th, 2020 • Axsome Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledNovember 5th, 2020 Company Industry JurisdictionTHIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 5th, 2020 • Axsome Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledNovember 5th, 2020 Company Industry JurisdictionTHIS LOAN AND SECURITY AGREEMENT is made and dated as of September 25, 2020 and is entered into by and among AXSOME THERAPEUTICS, INC., a Delaware corporation, and each of its Subsidiaries other than Excluded Subsidiaries (individually and collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as the “Lenders”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the “Agent”).
DIRECT AGREEMENTDirect Agreement • November 5th, 2020 • Axsome Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledNovember 5th, 2020 Company Industry JurisdictionThis DIRECT AGREEMENT (this “Direct Agreement”), dated as of September 25, 2020, is by and among Antecip Bioventures II LLC, a Delaware limited liability company (the “Contracting Party”), Hercules Capital, Inc., as collateral agent for itself and the Lenders (as defined below) (in such capacity, together with its successors in such capacity, the “Agent”), and Axsome Therapeutics, Inc., a Delaware corporation (the “Company”).